AIV001 (axitinib)
Nodular and Superficial Basal Cell Carcinoma (Nonmelanoma Skin Cancer)
Phase 2Active
Key Facts
Indication
Nodular and Superficial Basal Cell Carcinoma (Nonmelanoma Skin Cancer)
Phase
Phase 2
Status
Active
Company
About AiViva BioPharma
AiViva BioPharma is a private, clinical-stage biotech leveraging its proprietary JEL Technology for enhanced drug delivery, primarily in dermatology and ophthalmology. Founded by industry veterans, the company employs a risk-mitigated development strategy to advance a pipeline of novel candidates, with its lead program, AIV001 (axitinib), having completed a Phase 2a study for nonmelanoma skin cancer. AiViva operates as a pre-revenue entity, positioning itself to address significant markets with high unmet need through localized, prolonged-action therapies.
View full company profile